Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M95.2Revenue (TTM) $M22.5Net Margin (%)-96.9Altman Z-Score-9.2
Enterprise Value $M91.7EPS (TTM) $-1.2Operating Margin %-91.2Piotroski F-Score4
P/E(ttm)--Beneish M-Score-2.7Pre-tax Margin (%)-97.3Higher ROA y-yN
Price/Book4.810-y EBITDA Growth Rate %--Quick Ratio1.6Cash flow > EarningsY
Price/Sales3.85-y EBITDA Growth Rate %--Current Ratio1.9Lower Leverage y-yY
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)-47.0Higher Current Ratio y-yY
Dividend Yield %--PEG--ROE % (ttm)-120.1Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M20.4ROIC % (ttm)-140.4Gross Margin Increase y-yY

Gurus Latest Trades with CRME

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
CRMEJulian Robertson 2012-12-31 Sold Out -0.11%$1.25 - $2.5
($1.57)
$ 4.82207%Sold Out0
CRMEJulian Robertson 2011-12-31 Reduce-0.48%$9.35 - $17.85
($13.05)
$ 4.82-63%Reduce -18.26%319,221
CRMEGeorge Soros 2011-12-31 Sold Out -0.0008%$9.35 - $17.85
($13.05)
$ 4.82-63%Sold Out0
CRMEJulian Robertson 2011-09-30 Reduce-0.69%$16.45 - $27.95
($19.94)
$ 4.82-76%Reduce -22.89%390,518
CRMEGeorge Soros 2011-09-30 Add$16.45 - $27.95
($19.94)
$ 4.82-76%Add 4.55%2,760
CRMEGeorge Soros 2011-06-30 Buy $19.25 - $28.85
($23.62)
$ 4.82-80%New holding2,640
CRMEJulian Robertson 2011-03-31 Add0.16%$21.3 - $34.95
($29.35)
$ 4.82-84%Add 6.15%506,468
CRMEJulian Robertson 2010-12-31 Add0.34%$23 - $32.75
($27.98)
$ 4.82-83%Add 9.55%477,123
CRMEGeorge Soros 2010-12-31 Sold Out $23 - $32.75
($27.98)
$ 4.82-83%Sold Out0
CRMEJulian Robertson 2010-09-30 Add0.4%$29.85 - $46.55
($36.3)
$ 4.82-87%Add 10.01%435,523
CRMEGeorge Soros 2010-09-30 Reduce$29.85 - $46.55
($36.3)
$ 4.82-87%Reduce -3.67%2,100
CRMEJulian Robertson 2010-06-30 Buy 3.53%$33.05 - $43.4
($40.05)
$ 4.82-88%New holding395,881
CRMEGeorge Soros 2010-06-30 Buy $33.05 - $43.4
($40.05)
$ 4.82-88%New holding2,180
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

CRME is held by these investors:

No Entry found in the selected group of Gurus. You can
Premium Most recent portfolio changes are included for Premium Members only!


CRME: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Archibald, JenniferSenior Officer 2014-09-08Buy75$7.29-35.8view
Archibald, JenniferSenior Officer 2014-09-05Buy4,100$7.25-35.45view
Archibald, JenniferSenior Officer 2014-09-05Buy100$7.22-35.18view
Archibald, JenniferSenior Officer 2014-09-05Buy3,259$6.7-30.15view
Hunter, William L.Director, Senior Officer 2014-09-05Buy31,000$6.74-30.56view
Hunter, William L.Director, Senior Officer 2014-09-04Buy19,000$6.65-29.62view
RIEDER, ROBERTDirector, Director or Senior Officer of Insider or 2014-06-27Sell2,000$8.65-45.9view
RIEDER, ROBERTDirector, Director or Senior Officer of Insider or 2014-06-26Sell1,500$8.65-45.9view
RIEDER, ROBERTDirector, Director or Senior Officer of Insider or 2014-06-25Sell300$8.63-45.77view
RIEDER, ROBERTDirector, Director or Senior Officer of Insider or 2014-06-25Sell2,000$8.64-45.83view

Press Releases about CRME :

Quarterly/Annual Reports about CRME:

    News about CRME:

    Articles On GuruFocus.com
    A Closer Look Into Veritas Pharma Apr 21 2016 
    Julian Robertson’s "smart idea, grounded on exhaustive research, followed by a big bet" Jun 24 2011 
    Julian Robertson’s Tiger Management Q1 Portfolio Update May 16 2011 
    Julian Robertson Keeps Buying CRME, Selling AAPL Apr 13 2011 
    More Word of Wisdom from Julian Robertson; Top 2Q10 Purchases: GOOG, EBAY, AAPL, CRME, GS Nov 04 2010 

    More From Other Websites
    Cardiome Pharma Corp. :CRME-US: Earnings Analysis: Q1, 2016 By the Numbers : May 23, 2016 May 23 2016
    Cardiome Pharma (CRME) Jumps: Stock Moves 8.1% Higher May 23 2016
    Cardiome Reports First Quarter 2016 Financial Results May 13 2016
    Cardiome reports 1Q loss May 13 2016
    Cardiome reports 1Q loss May 13 2016
    Cardiome Reports First Quarter 2016 Financial Results May 13 2016
    Cardiome Reports First Quarter 2016 Financial Results May 13 2016
    Cardiome Announces the Launch of ESMOCARD Solution for Injection in France May 12 2016
    Cardiome Announces the Launch of ESMOCARD Solution for Injection in France May 12 2016
    Cardiome Announces the Launch of ESMOCARD Solution for Injection in France May 12 2016
    Cardiome Announces Publication of Spanish Emergency Department BRINAVESS Study May 11 2016
    Cardiome to Hold First Quarter 2016 Financial Results Conference Call on May 13 May 11 2016
    Cardiome Announces Publication of Spanish Emergency Department BRINAVESS Study May 11 2016
    Cardiome to Hold First Quarter 2016 Financial Results Conference Call on May 13 May 11 2016
    Cardiome Announces Publication of Spanish Emergency Department BRINAVESS Study May 11 2016
    Cardiome to Hold First Quarter 2016 Financial Results Conference Call on May 13 May 11 2016
    Drug Stocks Q1 Earnings Slated on May 11: ACRS, EARS & More May 10 2016
    Cardiome and Allergan Announce XYDALBA™ (Dalbavancin) Licensing Agreement in International Markets May 05 2016
    Cardiome and Allergan Announce XYDALBA™ (Dalbavancin) Licensing Agreement in International Markets May 05 2016
    Cardiome and Allergan Announce XYDALBA™ (Dalbavancin) Licensing Agreement in International Markets May 05 2016

    Add Notes, Comments

    If you want to ask a question or report a bug, please create a support ticket.
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)